CDMO
UCB Announces FDA Approvals for BIMZELX for Psoriatic Arthritis, Axial Spondyloarthritis, and Ankylosing Spondylitis
UCB
PR-09-24-NI-13Sep 23, 2024
Expansion
UCB to Build New Biotech Manufacturing Plant in Belgium
UCB
PR-M01-20-NI-004Jan 02, 2020
FDA Approval
CIMZIA® (certolizumab pegol) is Now the First and Only U.S. FDA-Approved Treatment for Non-Radiographic Axial Spondyloarthritis
UCB
PR-M04-19-NI-013Apr 04, 2019
FDA Approval
UCB Given FDA Okay for Anti-Arthritis Drug
Emilie Branch
Pharma's Almanac
PAO-M04-19-NI-008Apr 02, 2019
Acquisition
UCB Strengthens Research Capabilities With Acquisition of Element Genomics, a Duke University Biotech Spin-off
UCB
PR-M04-18-NI-32Apr 10, 2018
Innovation
CIMZIA® (certolizumab pegol) Label Change Marks Important Advance for European Women of Childbearing Age With Chronic Rheumatic Disease
UCB
PR-M01-18-NI-036Jan 12, 2018